Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Enanta Pharmaceuticals (ENTA) PT Lowered to $90 at RBC Capital
August 8, 2018 8:33 AM EDTRBC Capital lowered its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $90.00 (from $111.00) while maintaining a Sector Perform rating.
... MoreEnanta Pharma (ENTA) Misses Q3 EPS by 1c
August 7, 2018 4:04 PM EDTEnanta Pharma (NASDAQ: ENTA) reported Q3 EPS of $0.97, $0.01 worse than the analyst estimate of $0.98. Revenue for the quarter came in at $57.3 million versus the consensus estimate of $56.93 million.
For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.
... More